Orum Therapeutics doses first patient in Phase 1 trial of AML drug candidate ORM — 1153
Orum Therapeutics dosed the first patient in a Phase 1 trial of ORM-1153 for relapsed or refractory AML. No clinical results have been presented; the study is designed to generate initial safety, pharmacology, and early activity readouts. Program targets CD123 with a GSPT1 degrader payload, positioning it as a new appr